Nittner-Marszalska Marita, Rosiek-Biegus Marta, Kopeć Agnieszka, Pawłowicz Robert, Kosińska Magdalena, Łata Aleksandra, Szenborn Leszek
Department and Clinic of Internal Medicine, Pneumology and Allergology, Wroclaw Medical University, Str. Marii Skłodowskiej-Curie 66, 50-369 Wrocław, Poland.
Department of Paediatrics and Infectious Diseases, Wroclaw Medical University, Str. Chałubińskiego 2-2a, 50-368 Wrocław, Poland.
Vaccines (Basel). 2021 May 25;9(6):553. doi: 10.3390/vaccines9060553.
Individuals with a history of allergy are potentially at risk of suffering from adverse effects after COVID-19 vaccination. We sought to assess the tolerance towards the Pfizer-BioNTech vaccine in allergic patients. To address this issue, we used a questionnaire conducted on-line in a group of medical professionals who were vaccinated with the Pfizer-BioNTech vaccine. A total of 1808 respondents, out of whom 1707 received two doses of the vaccine, returned the questionnaire. Local reactions after injection were more frequent in allergic individuals after both doses (swelling = 0.0003). Systemic adverse events (AE-SYS) occurred more often after the second than the first dose in both groups (allergic persons: 77.29% vs. 41.06%); vomiting and arthralgia occurred more often in allergic subjects ( = 0.0009). AE-SYS in allergic individuals lasted longer than in non-allergic ones after the first ( = 0.01) and the second dose ( = 0.0009). Allergic reactions after vaccination were reported more frequently in allergic subjects: after the first dose ( = 0.00001) and after the second dose ( = 0.001). Rhinitis was the most frequent symptom observed more often in allergic patients. No severe allergic reactions occurred during the full cycle of vaccination. Although the Pfizer-BioNTech vaccine is tolerated worse by allergic than non-allergic individuals, the occurring adverse symptoms are mild and do not preclude a successful completion of the vaccination cycle. The presence of symptoms suggestive of allergy does not constitute a condition of increased risk of developing clinically significant adverse events following Pfizer COVID-19 vaccination.
有过敏史的个体在接种新冠疫苗后可能有出现不良反应的风险。我们试图评估过敏患者对辉瑞 - 生物科技疫苗的耐受性。为解决这个问题，我们对一组接种了辉瑞 - 生物科技疫苗的医学专业人员进行了在线问卷调查。共有1808名受访者回复了问卷，其中1707人接种了两剂疫苗。两剂疫苗接种后，过敏个体的局部反应更频繁（肿胀 = 0.0003）。两组中，第二次接种后全身不良事件（AE - SYS）的发生频率均高于第一次（过敏者：77.29% 对 41.06%）；呕吐和关节痛在过敏受试者中更常见（ = 0.0009）。第一次（ = 0.01）和第二次接种后（ = 0.0009），过敏个体的AE - SYS持续时间比非过敏个体更长。过敏受试者接种疫苗后的过敏反应报告更频繁：第一次接种后（ = 0.00001）和第二次接种后（ = 0.001）。鼻炎是过敏患者中最常观察到的症状。在整个疫苗接种周期中未发生严重过敏反应。尽管过敏个体对辉瑞 - 生物科技疫苗的耐受性比非过敏个体差，但出现的不良症状较轻，并不妨碍成功完成疫苗接种周期。出现提示过敏的症状并不构成辉瑞新冠疫苗接种后发生具有临床意义的不良事件风险增加的情况。
